Tau positron emission tomographic imaging in aging and early A lzheimer disease
Boston University · Brigham and Women's Hospital · +5 more institutions
Abstract
Detection of focal brain tau deposition during life could greatly facilitate accurate diagnosis of Alzheimer disease (AD), staging and monitoring of disease progression, and development of disease-modifying therapies.
We acquired tau positron emission tomography (PET) using (18)F T807 (AV1451), and amyloid-β PET using (11)C Pittsburgh compound B (PiB) in older clinically normal individuals, and symptomatic patients with mild cognitive impairment or mild AD dementia.
Citation impact
- FWCI
- 56.56
- Percentile
- 100%
- References
- 39
Authors
24- KAKeith A. JohnsonCorresponding
Boston University, Brigham and Women's Hospital, Boston Medical Center, Harvard University, Society of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital
- APAaron P. Schultz
Brigham and Women's Hospital, Society of Nuclear Medicine and Molecular Imaging, Athinoula A. Martinos Center for Biomedical Imaging
- RARebecca A. Betensky
Harvard University, Massachusetts General Hospital
- JAJ. Alex Becker
Society of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital
- JSJorge Sepulcre
Harvard University, Society of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging
Topics & keywords
- Tauopathy
- Neuropathology
- Positron emission tomography
- Dementia
- Pittsburgh compound B
- Biomarker
- Neuroscience
- Medicine
- Good health and well-being